Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of Sutent versus placebo in advanced pancreatic islet cell tumors
2006-004022-87Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in islet cell tumor comparing Sutent with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Feb 2007; status: terminated.
02
Drugs
sunitinib
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2006-004022-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004022-87.